Ranbaxy, Cipla in alliance

By Our Staff Correspondent

MUMBAI, AUG. 28. Ranbaxy and Cipla have announced their alliance to co-market Ranbaxy's once-a-day formulation of Ciprofloxacin, which has recently received DCGI (Drug Controller General of India) approval for marketing in India. This unique dosage form of the broad-spectrum anti-bacterial, is from Ranbaxy's Novel Drug Delivery Systems (NDDS) research pipeline.

Dr. Brian W. Tempest, president, Pharmaceuticals, Ranbaxy Laboratories, said, ``The Ranbaxy-Cipla alliance will be a win- win situation for both companies, enabling to leverage its combined marketing prowess and extensive distribution network. We are keen that the benefits of Ciprofloxacin OD in terms of convenience and better patient compliance should percolate to the maximum number of doctors and patients.''

Mr. Amar Lulla, joint managing director, Cipla said, ``The spirit of co-operation that was started a few years ago between Cipla and Ranbaxy has now been strengthened with the Ciprofloxacin OD agreement. Together, both our brands account for over 30 per cent of the Ciprofloxacin market and thus we will be in better position to convert the market towards the once-daily concept in this fragmented segment.''

The development of the once-daily formulation of Ciprofloxacin will give a cutting edge to both companies for further consolidating their market share. The companies would be marketing the product under their brand names - Cifran OD (Ranbaxy) and Ciplox OD (Cipla). Ranbaxy would manufacture the products for both companies.

Send this article to Friends by E-Mail

Section  : Business
Previous : Bharti finalises $150 m pact with 3 major
           suppliers
Next     : Sundaram Newton revamps liquid fund offer